Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2000 1
2002 1
2006 2
2009 2
2010 2
2011 2
2012 3
2013 1
2014 2
2015 2
2016 4
2017 6
2018 9
2019 4
2020 12
2021 6
2022 6
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5. Cochrane Database Syst Rev. 2022. PMID: 35603936 Free PMC article. Updated. Review.
Network meta-analysis at class level showed that all interventions (non-biological systemic agents, small molecules, and biological treatments) showed a higher proportion of patients reaching PASI 90 than placebo. Anti-IL17 treatment showed a higher proportion of patients …
Network meta-analysis at class level showed that all interventions (non-biological systemic agents, small molecules, and biological treatmen …
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Review.
Bimekizumab and ixekizumab were significantly more likely to reach PASI 90 than secukinumab. Bimekizumab, ixekizumab, and risankizumab were significantly more likely to reach PASI 90 than brodalumab and guselkumab. ...The findings therefore have to be viewed with ca …
Bimekizumab and ixekizumab were significantly more likely to reach PASI 90 than secukinumab. Bimekizumab, ixekizumab, and risankizuma …
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. PMID: 33871055 Free PMC article. Updated.
Network meta-analysis also showed that infliximab, ixekizumab, risankizumab, bimekizumab, secukinumab, guselkumab, and brodalumab outperformed other drugs when compared to placebo in reaching PASI 90. The clinical effectiveness of these drugs was similar, except for ixekiz …
Network meta-analysis also showed that infliximab, ixekizumab, risankizumab, bimekizumab, secukinumab, guselkumab, and brodalumab outperform …
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3. Cochrane Database Syst Rev. 2020. PMID: 31917873 Free PMC article. Updated.
At drug level, in terms of reaching PASI 90, infliximab, all of the anti-IL17 drugs (ixekizumab, secukinumab, bimekizumab and brodalumab) and the anti-IL23 drugs (risankizumab and guselkumab, but not tildrakizumab) were significantly more effective in reaching PASI …
At drug level, in terms of reaching PASI 90, infliximab, all of the anti-IL17 drugs (ixekizumab, secukinumab, bimekizumab and brodalu …
Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study.
Stingeni L, Malara G, Conti A, Di Costanzo L, Carrera CG, Burlando M, Malagoli P, Musumeci ML, Bardazzi F, Brazzelli V, Amerio P, De Simone C, Trevisini S, Balato A, Megna M, Loconsole F, De Felice C, Bartezaghi M, Rausa A, Aloisi E, Orsenigo R, Costanzo A; SUPREME Study Group. Stingeni L, et al. Clin Cosmet Investig Dermatol. 2023 Jan 5;16:27-38. doi: 10.2147/CCID.S378135. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 36636635 Free PMC article.
PATIENTS AND METHODS: The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. ...No differences were observed between genders in PASI 100/75 responses at week 24. Both genders showed an improvement in DLQI with secu …
PATIENTS AND METHODS: The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. ...N …
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
Lasagna A, Mele D, Bergami F, Alaimo D, Dauccia C, Alessio N, Comolli G, Pasi F, Muzzi A, Novelli V, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Hum Vaccin Immunother. 2023 Dec 15;19(3):2288282. doi: 10.1080/21645515.2023.2288282. Epub 2023 Dec 1. Hum Vaccin Immunother. 2023. PMID: 38037900 Free PMC article.
67 results